Actively Recruiting

Phase Not Applicable
Age: 20Years - 75Years
All Genders
NCT07065383

Rebalancing the Fat Content of the Heart and Muscles

Led by University of Aberdeen · Updated on 2026-04-30

60

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

Sponsors

U

University of Aberdeen

Lead Sponsor

N

NHS Grampian

Collaborating Sponsor

AI-Summary

What this Trial Is About

Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.

CONDITIONS

Official Title

Rebalancing the Fat Content of the Heart and Muscles

Who Can Participate

Age: 20Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 20 to 75 years with a confirmed diagnosis of type 2 diabetes within the last 10 years
  • HbA1c level at or above 53 mmol/mol (7%) typically treated with diet and/or metformin, sulphonylureas, SGLT-2 inhibitors, DPP-4 inhibitors, or thiazolidinediones, but not insulin
  • Patients not meeting WHO recommendations of at least 150 minutes per week of moderate to vigorous physical activity
  • Body mass index (BMI) of 27 or higher with body weight less than 140 kg
  • Estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73m2 within the last 3 months
  • Able to understand written and spoken English
Not Eligible

You will not qualify if you...

  • Any previously unknown cardiac condition other than mild valvular disease
  • History of known coronary artery disease including myocardial infarction
  • Untreated or relevant endocrine conditions such as Cushing's disease
  • Impaired kidney function with eGFR less than 30 mL/min/1.73m2
  • Blood pressure above 180/100 mmHg
  • Use of medications affecting glucose or fatty acid metabolism such as niacin, omega-3 fatty acids, or other GLP-1 receptor agonists
  • Dietary habits that may interfere with the study, for example high fat vegan diets
  • Medical or surgical conditions that interfere with exercise or fatty acid metabolism or affect safety, such as peripheral vascular disease, arthritis, neurological syndromes, or lipid storage diseases
  • Known sensitivity to semaglutide, diabetic retinopathy, pregnancy, history of pancreatitis or cancer
  • Significant asthma or pulmonary disease
  • Inability to use a cycling ergometer or perform exercise testing
  • Pregnancy, breastfeeding, or planning pregnancy
  • Recent gastrointestinal contrast or radionuclide use
  • Inability to lie flat or remain still for scanning procedures
  • Body size preventing fit into the magnetic resonance scanner
  • Lack of ability or motivation to follow a physical training program
  • Current participation in other interventional clinical research
  • Inability to understand written or spoken English

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cardiac Research Office, Aberdeen Royal Infirmary

Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZD

Actively Recruiting

Loading map...

Research Team

A

Alexander Davidson, DM

CONTACT

A

Amelia E Rudd, MSc, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here